To use all functions of this page, please activate cookies in your browser.
my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
Researchers from the University of Basel and Syngenta decode the genome of a plant fungus
04-08-2002: Basel, Switzerland. The Biozentrum (Biocentre) of the University of Basel and Syngenta AG will announce today that they have successfully sequenced the genome of the plant pathogenic Ashbya gossypii fungus. This is the first time that the genome of such a fungus has been analyzed. The complete genetic map is of both great scientific value and far reaching practical significance and has already yielded surprising results in basic research, also in the area of genome evolution. Agricultural research will also benefit, e.g. through the functional analysis of important proteins.
Since its establishment in 1981, the Applied Microbiology Research Unit at the Biozentrum of the University of Basel has been carrying out research into Ashbya gossypii. Since 1997, the university has been working on the systematic analysis of its genome in collaboration with Syngenta. This fungus is of major interest because it possesses the smallest known genome of a eukaryote (organisms with nuclei), which consists of nine million base pairs distributed on 7 chromosomes. The composition of the 4720 proteins encoded in the genome is now known.
The Ashbya genome does not have any direct commercial benefit. However, science will use the insight gained from this genome to more quickly and securely recognize the gene function and effect from plant and human pathogenic fungi. Scientists at the Biozentrum and the Swiss Institute of Bioinformatics support the establishment of an Ashbya genome database that will be available to all interested parties. The collaboration between industry and academia has proved its worth in this project.
“We are very proud that we have been able to carry out pioneering work in this area and that our innovative approach has been successful,” says Prof. Peter Philippsen, Team Leader of the Applied Microbiology Research Unit. “Without the major professional collaboration and the financial support of Syngenta, we would not have been able to succeed with such a small team in this challenging scientific task.”
For Syngenta this scientific breakthrough could bring an improved approach in the search for new fungicides. “This is truly an excellent achievement which has produced a great body of useful research,” says Dr. David Evans, Head of Research & Technology at Syngenta. “This will now provide an efficient and innovative platform in the search for new methods of crop protection.”
Watchlist
This is where you can add this news to your personal favourites
- 1Glucose uptake relies on newly identified protein
- 2Drug companies enter Indonesia and the Philippines
- 3Pharmexa A/S sells Pharmexa-Epimmune to the Korean company VaxOnco, Inc.
- 4Nexia Biotechnologies to reorganize into oil and gas company
- 5Bayer acquires exclusive rights to Bioton’s insulin SciLin
- 6Bayer’s Novel Anticoagulant Xarelto now also Approved in the EU
- 7AiCuris’ Novel HSV Compound AIC316 Shows Efficacy in Phase II
- 8Nomad Bioscience: new plant biotechnology company founded to focus on biomaterials and biopharmaceuticals
- 9Biotech companies in the future among top 10 drug sellers / winners & losers of the pharmaceutical industry in the next decade
- 10M&A Trends in Pharma-Biotech: An Analysis of a Business Model
- Children with rare, incurable brain disease improve after gene therapy
- First, do no harm: Study finds danger in standard treatment for a serious lu ...
- Scientists identify new target to battle rheumatoid arthritis
- Heparin-like compounds inhibit breast cancer metastasis to bone
- Tiny tool can play big role against tuberculosis
- Affimed joins the Molecular Imaging Technology Initiative - - BMBF awards Affimed a funding grant of €550K
- Biotech companies in the future among top 10 drug sellers / winners & losers of the pharmaceutical industry in the next decade - - Of today’s top ten best-selling drugs only four will be left over in 2012
- Bayer’s Novel Anticoagulant Xarelto now also Approved in the EU - - Bayer will start marketing the new oral, once-daily anticoagulant very soon / First-in-class product to demonstrate superior efficacy to current standard of care
- Nomad Bioscience: new plant biotechnology company founded to focus on biomaterials and biopharmaceuticals -
- Affimed appoints Chief Business Officer -
